Precision BioSciences to Present at Upcoming Virtual Investor Conferences in October
Precision BioSciences (Nasdaq: DTIL), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences on October 5, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Precision BioSciences (Nasdaq: DTIL), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences on October 5, 2020. The conferences include the Chardan 4th Annual Genetic Medicines Conference, scheduled for 8:30 AM ET, and the Jefferies Cell Therapy Summit, starting at 5:30 PM ET. Live webcasts will be accessible on the company’s website, with archived replays available for 30 days post-event. Precision BioSciences utilizes its ARCUS genome editing platform to develop innovative therapies for genetic and infectious diseases.
Details
News Market Reaction – DTIL
The recorded move for DTIL in the trading session of this news was +5.71%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DURHAM, N.C., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, today announced its participation in the following upcoming virtual investor conferences:
- Chardan 4th Annual Genetic Medicines Conference
Date: Monday, October 5, 2020
Time: 8:30 – 9:00 AM ET - Jefferies Cell Therapy Summit
Date: October 5, 2020
Time: 5:30 – 6:00 PM ET
Live webcasts of each presentation will be accessible on the Company’s website www.precisionbiosciences.com, under the Investors & Media section. An archived replay of the webcasts will be available for approximately 30 days following the presentations.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences please visit www.precisionbiosciences.com.
Investor and Media Contact:
Maurissa Messier
Senior Director, Corporate Communications
maurissa.messier@precisionbiosciences.com
Josh Rappaport
Stern Investor Relations
josh.rappaport@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.